Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported initiation of an expanded part of CAN10's phase 1 clinical study to investigate higher dose levels of the antibody. The purpose of this ...

Francis S. Kim, MD, has made significant contributions to biomedical research and clinical care for adult and pediatric ...

The drug survival for adalimumab is significantly higher than that of infliximab in pediatric patients with hidradenitis suppurativa (HS), results from a small single-center study showed.

Medically reviewed by Susan Bard, MD An inner thigh rash is a skin irritation that develops on the inner portion of your ...

The U.S. Food and Drug Administration has approved UCB's Bimzelx (bimekizumab-bkzx) for the treatment of adults with moderate ...

The Food and Drug Administration (FDA) has approved Bimzelx ® (bimekizumab-bkzx) for the treatment of moderate to severe hidradenitis suppurativa (HS) in adults.

The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...

Hidradenitis suppurativa (HS) is an immune disease that affects up to 4% of the global population and causes painful, recurring skin lesions and inflammation, primarily in the folds of the skin. It ...

The research, which was published in the journal Proceedings of the National Academy of Sciences (PNAS), offers a promising target for future therapies. Hidradenitis suppurativa (HS) is an immune ...

Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF) IND enabling studies underway, with Phase I ...

MoonLake Immunotherapeutics' shares have dipped recently, with a catalyst vacuum until mid-2025 when pivotal trial data for ...

The novel IL-17A and IL-17F inhibitor has been approved for moderate to severe hidradenitis suppurativa, a chronic and ...